VBI Vaccines (NASDAQ:VBIV) released its quarterly earnings data on Friday. The biopharmaceutical company reported ($0.04) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.04), MarketWatch Earnings reports. The firm had revenue of $0.18 million during the quarter, compared to the consensus estimate of $0.86 million. VBI Vaccines had a negative return on equity of 57.79% and a negative net margin of 2,133.79%.
VBI Vaccines stock opened at $4.07 on Friday. VBI Vaccines has a fifty-two week low of $0.47 and a fifty-two week high of $6.93. The firm’s 50-day simple moving average is $3.66 and its 200 day simple moving average is $1.99. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.28 and a current ratio of 1.30.
Several equities research analysts have recently commented on VBIV shares. BidaskClub downgraded VBI Vaccines from a “strong-buy” rating to a “buy” rating in a report on Tuesday, July 28th. Oppenheimer increased their price target on VBI Vaccines from $5.00 to $8.00 and gave the company an “outperform” rating in a research report on Tuesday, June 23rd. Zacks Investment Research downgraded shares of VBI Vaccines from a “hold” rating to a “sell” rating in a report on Saturday, July 11th. Raymond James upped their target price on shares of VBI Vaccines from $3.00 to $8.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 22nd. Finally, ValuEngine downgraded shares of VBI Vaccines from a “buy” rating to a “hold” rating in a report on Thursday, July 2nd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and five have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $5.10.
VBI Vaccines Company Profile
VBI Vaccines Inc, a biopharmaceutical company, develops and sells vaccines to address unmet needs in infectious disease and immuno-oncology in Israel and internationally. The company offers Sci-B-Vac, a prophylactic hepatitis B vaccine for adults, children, and newborns; and eVLP, a vaccine platform for the design of enveloped virus-like particle vaccines that closely mimic the structure of the target virus.
Recommended Story: The basics of gap trading strategies
Receive News & Ratings for VBI Vaccines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VBI Vaccines and related companies with MarketBeat.com's FREE daily email newsletter.